{"nctId":"NCT04423718","briefTitle":"Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye","startDateStruct":{"date":"2020-08-11","type":"ACTUAL"},"conditions":["Neovascular Age-Related Macular Degeneration"],"count":1011,"armGroups":[{"label":"Aflibercept 2q8","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)","Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)"]},{"label":"Aflibercept HDq12","type":"EXPERIMENTAL","interventionNames":["Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)"]},{"label":"Aflibercept HDq16","type":"EXPERIMENTAL","interventionNames":["Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)"]}],"interventions":[{"name":"Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)","otherNames":[]},{"name":"Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Active subfoveal CNV secondary to nAMD, including juxtafoveal lesions that affect the fovea as assessed in the study eye.\n* Total area of CNV (including both classic and occult components) must comprise greater than 50% of the total lesion area in the study eye.\n* BCVA ETDRS letter score of 78 to 24 (corresponding to a Snellen equivalent of approximately 20/32 to 20/320) in the study eye.\n* Decrease in BCVA determined to be primarily the result of nAMD in the study eye.\n* Presence of IRF and/or SRF affecting the central subfield of the study eye on OCT.\n* Contraceptive use by men or women should be consistent with local regulations regarding the methods of highly effective contraception for those participating in clinical studies.\n* Other protocol-specified inclusion criteria.\n\nAdditional inclusion criteria for Year 3:\n\n* At least one BCVA value and one central subfield retinal thickness (CST) value from measurements at one of the following visits: Visit 24 (Week 84), Visit 25 (Week 88) or Visit 26 (Week 92).\n* Participant is enrolled at a site that participates in the extension period.\n\nExclusion Criteria:\n\n* Causes of CNV other than nAMD in the study eye.\n* Scar, fibrosis, or atrophy involving the central subfield in the study eye.\n* Presence of retinal pigment epithelial tears or rips involving the central subfield in the study eye.\n* Uncontrolled glaucoma (defined as IOP \\>25 mmHg despite treatment with anti-glaucoma medication) in the study eye.\n* History of idiopathic or autoimmune uveitis in the study eye.\n* Myopia of a spherical equivalent of at least 8 diopters in the study eye prior to any refractive or cataract surgery.\n* History or clinical evidence of diabetic retinopathy, diabetic macular edema, or any retinal vascular disease other than nAMD in either eye.\n* Evidence of extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening/randomization.\n* Uncontrolled blood pressure (defined as systolic \\>160 mmHg or diastolic \\>95 mmHg).\n* Any prior or concomitant ocular (in the study eye) or systemic treatment (with an investigational or approved, anti-VEGF or other agent) or surgery for nAMD, except dietary supplements or vitamins.\n* Other protocol-specified exclusion criteria","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48","description":"Visual function of the study eye was assessed at a distance of 4 meters using the ETDRS BCVA letter score. BCVA scale range is 0 (worst) to 100 (best).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.03","spread":"0.74"},{"groupId":"OG001","value":"6.06","spread":"0.77"},{"groupId":"OG002","value":"5.89","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 60","description":"Visual function of the study eye was assessed at a distance of 4 meters using the ETDRS BCVA letter score. BCVA scale range is 0 (worst) to 100 (best).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.23","spread":"0.68"},{"groupId":"OG001","value":"6.37","spread":"0.74"},{"groupId":"OG002","value":"6.31","spread":"0.66"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With no Intraretinal Fluid (IRF) and no Subretinal Fluid (SRF) in Central Subfield at Week 16","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null},{"groupId":"OG001","value":"61.6","spread":null},{"groupId":"OG002","value":"65.0","spread":null},{"groupId":"OG003","value":"63.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Gaining at Least 15 Letters in BCVA From Baseline at Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"20.7","spread":null},{"groupId":"OG002","value":"21.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":null},{"groupId":"OG001","value":"56.9","spread":null},{"groupId":"OG002","value":"54.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Choroidal Neovascularization (CNV) Size From Baseline to Week 48","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.43","spread":"0.31"},{"groupId":"OG001","value":"-3.65","spread":"0.28"},{"groupId":"OG002","value":"-2.91","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Change in Total Lesion Area From Baseline to Week 48","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.22"},{"groupId":"OG001","value":"-0.46","spread":"0.19"},{"groupId":"OG002","value":"-0.35","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With no Intraretinal Fluid (IRF) and no Subretinal Fluid (SRF) in the Center Subfield at Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"71.1","spread":null},{"groupId":"OG002","value":"66.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 48","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-136.25","spread":"4.24"},{"groupId":"OG001","value":"-147.37","spread":"4.01"},{"groupId":"OG002","value":"-146.76","spread":"3.76"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Total Score at Week 48","description":"NEI VFQ-25 was a 25-item questionnaire that gave a score on a scale from 0 (worst) to 100 (best = no vision problems)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","spread":"0.70"},{"groupId":"OG001","value":"3.50","spread":"0.70"},{"groupId":"OG002","value":"3.35","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Week 48","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"70.29"},{"groupId":"OG001","value":"0.14","spread":"78.69"},{"groupId":"OG002","value":"0.13","spread":"82.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"0.02","spread":"81.35"},{"groupId":"OG002","value":"0.02","spread":"84.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":69,"n":336},"commonTop":["COVID-19","Cataract","Nasopharyngitis","Hypertension","Visual acuity reduced"]}}}